Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of 1 of the following: Acute myeloid leukemia (Acute promyelocytic leukemia (M3) allowed provided patient has failed prior therapy with both tretinoin and arsenic alone or in combination); Acute lymphoblastic leukemia; Myelodysplastic syndromes; Blastic phase chronic myelogenous leukemia (Failed OR intolerant to imatinib mesylate)~* Must have failed prior therapy with \>= 1 cytotoxic- or biologic-targeted agent (e.g., hypomethylating agents, farnesyl transferase inhibitors, thalidomide, or tyrosine kinase inhibitors); Any number of prior regimens allowed~* Performance status: ECOG 0-1~* ALT =\< 2.5 times upper limit of normal~* Bilirubin =\< 1.5 mg/dL~* Creatinine =\< 2.0 mg/dL OR Creatinine clearance \>= 60 mL/min~* Fertile patients must use effective contraception~* No psychiatric illness or social situation that would preclude study compliance~* Prior bone marrow transplantation allowed~* At least 2 weeks since prior cytotoxic agents OR at least 5 half-lives for non-cytotoxic agents in the absence of rapidly progressing disease~* At least 24 hours since prior hydrea for control of peripheral blood leukemia cell counts~* Hydroxyurea allowed up to 72 hours after start of therapy with sorafenib~* No persistent, chronic, clinically significant toxicities \> grade 1 from prior chemotherapy~Exclusion Criteria:~* Cytopenias secondary to multilineage bone marrow failure allowed~* Ineligible for or not willing to undergo allogeneic stem cell transplantation OR no donor available~* Absolute blast count=\< 20,000/mm\^3 unless patient has documented fms-like tyrosine kinase 3 internal tandem duplication~* No evidence of bleeding diathesis (except due to low platelets associated with the primary disease)~* No New York Heart Association class III or IV congestive heart failure~* No uncontrolled hypertension (i.e., sustained systolic blood pressure \[BP\] \>= 150 mm Hg or diastolic BP \>= 90 mm Hg)~* No unstable angina pectoris~* No symptomatic cardiac arrhythmia requiring and not responding to medical intervention~* Not pregnant or nursing~* No history of allergic reaction attributed to compounds of similar chemical or biological composition to the study drug~* No swallowing dysfunction that would impede oral ingestion of tablets~* No active uncontrolled infection~* No other uncontrolled illness~* No prior sorafenib~* No other concurrent investigational or commercial agents, except for standard intrathecal chemotherapy for the treatment of isolated CNS leukemic involvement~* No other concurrent anticancer agents~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent therapeutic anticoagulation (Concurrent prophylactic anticoagulation \[i.e., low-dose warfarin, catheter flushing with heparin\] of venous or arterial access devices allowed)~* No concurrent cytochrome P450 enzyme-inducing antiepileptic agents, including, but not limited to, any of the following: Phenytoin; Carbamazepine; Phenobarbital; Rifampin~* No concurrent Hypericum perforatum (St. John's wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
- Arm II (Type: EXPERIMENTAL): Patients receive oral sorafenib once or twice daily on days 1-14.

Based on this trial design, predict the completion outcome and termination type (if applicable).